{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T19:31:30Z","timestamp":1782934290664,"version":"3.54.5"},"reference-count":15,"publisher":"American Association for Cancer Research (AACR)","issue":"3","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,5,5]]},"abstract":"<jats:sec>\n                    <jats:title>Summary:<\/jats:title>\n                    <jats:p>Since the recognition of the allogeneic graft-versus-leukemia effect, acute myeloid leukemia (AML) has been identified as a T cell\u2013targetable malignancy, but success with modern forms of immunotherapy has been slower than anticipated. In this issue, we discuss the biological barriers to the treatment of AML with T-cell therapy revealed by recent reports, including mechanistic insights into AML resistance to T cell\u2013mediated killing by Tin and colleagues.<\/jats:p>\n                    <jats:p>See related article by Tin et al., p. 217<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2643-3230.bcd-25-0017","type":"journal-article","created":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T10:31:22Z","timestamp":1744799482000},"page":"157-158","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["The Paradox of Acute Myeloid Leukemia Responsiveness to Adoptive T-cell Therapy"],"prefix":"10.1158","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8044-5226","authenticated-orcid":false,"given":"Terry J.","family":"Fry","sequence":"first","affiliation":[{"name":"Gates Institute; Pediatrics and Immunology, University of Colorado Anschutz Medical Campus, Aurora, Colorado."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2025,4,16]]},"reference":[{"key":"2026041309322614200_bib1","first-page":"372","article-title":"Mechanisms of resistance to CAR T cell therapy","volume":"16","author":"Shah","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"2026041309322614200_bib2","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1056\/NEJMoa0811036","article-title":"Loss of mismatched HLA in leukemia after stem-cell transplantation","volume":"361","author":"Vago","year":"2009","journal-title":"N Engl J Med"},{"key":"2026041309322614200_bib3","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.1056\/NEJMoa1808777","article-title":"Immune escape of relapsed AML cells after allogeneic transplantation","volume":"379","author":"Christopher","year":"2018","journal-title":"N Engl J Med"},{"key":"2026041309322614200_bib4","doi-asserted-by":"crossref","first-page":"e003149","DOI":"10.1136\/jitc-2021-003149","article-title":"Systematic preclinical evaluation of CD33-directed chimeric antigen receptor T cell immunotherapy for acute myeloid leukemia defines optimized construct design","volume":"9","author":"Qin","year":"2021","journal-title":"J Immunother Cancer"},{"key":"2026041309322614200_bib5","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1182\/blood.2024024063","article-title":"Honing CAR T cells to tackle acute myeloid leukemia","volume":"145","author":"Haubner","year":"2025","journal-title":"Blood"},{"key":"2026041309322614200_bib6","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1182\/blood.2024024861","article-title":"Nanobody-based naturally selected CD7-targeted CAR-T therapy for acute myeloid leukemia","volume":"145","author":"Lu","year":"2025","journal-title":"Blood"},{"key":"2026041309322614200_bib7","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1158\/2643-3230.BCD-24-0140","article-title":"SOCS1 protects acute myeloid leukemia against allogeneic T cell-mediated cytotoxicity","volume":"6","author":"Tin","year":"2025","journal-title":"Blood Cancer Discov"},{"key":"2026041309322614200_bib8","doi-asserted-by":"crossref","first-page":"3697","DOI":"10.1038\/s41591-024-03271-5","article-title":"Cytokine-mediated CAR T therapy resistance in AML","volume":"30","author":"Bhagwat","year":"2024","journal-title":"Nat Med"},{"key":"2026041309322614200_bib9","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1038\/s43018-023-00570-7","article-title":"Tumor-intrinsic sensitivity to the pro-apoptotic effects of IFN-gamma is a major determinant of CD4+ CAR T-cell antitumor activity","volume":"4","author":"Boulch","year":"2023","journal-title":"Nat Cancer"},{"key":"2026041309322614200_bib10","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1158\/2643-3230.BCD-21-0181","article-title":"Blockade or deletion of IFN\u03b3 reduces macrophage activation without compromising CAR T-cell function in hematologic malignancies","volume":"3","author":"Bailey","year":"2022","journal-title":"Blood Cancer Discov"},{"key":"2026041309322614200_bib11","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41586-022-04585-5","article-title":"CAR T cell killing requires the IFN\u03b3R pathway in solid but not liquid tumours","volume":"604","author":"Larson","year":"2022","journal-title":"Nature"},{"key":"2026041309322614200_bib12","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1158\/2159-8290.CD-20-1661","article-title":"IFN\u03b3 is critical for CAR T cell-mediated myeloid activation and induction of endogenous immunity","volume":"11","author":"Alizadeh","year":"2021","journal-title":"Cancer Discov"},{"key":"2026041309322614200_bib13","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1038\/s41375-024-02255-1","article-title":"AML\/T cell interactomics uncover correlates of patient outcomes and the key role of ICAM1 in T cell killing of AML","volume":"38","author":"Sayitoglu","year":"2024","journal-title":"Leukemia"},{"key":"2026041309322614200_bib14","doi-asserted-by":"crossref","first-page":"8048","DOI":"10.1038\/s41467-023-43790-2","article-title":"Leukemia-intrinsic determinants of CAR-T response revealed by iterative in vivo genome-wide CRISPR screening","volume":"14","author":"Ramos","year":"2023","journal-title":"Nat Commun"},{"key":"2026041309322614200_bib15","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1038\/s41467-024-45916-6","article-title":"Comprehensive characterization of IFN\u03b3 signaling in acute myeloid leukemia reveals prognostic and therapeutic strategies","volume":"15","author":"Wang","year":"2024","journal-title":"Nat Commun"}],"container-title":["Blood Cancer Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/doi\/10.1158\/2643-3230.BCD-25-0017\/3588472\/bcd-25-0017.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/6\/3\/157\/3601181\/bcd-25-0017.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/6\/3\/157\/3601181\/bcd-25-0017.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T13:32:36Z","timestamp":1776087156000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article\/6\/3\/157\/762109\/The-Paradox-of-Acute-Myeloid-Leukemia"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,16]]},"references-count":15,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,4,16]]},"published-print":{"date-parts":[[2025,5,5]]}},"URL":"https:\/\/doi.org\/10.1158\/2643-3230.bcd-25-0017","relation":{},"ISSN":["2643-3230","2643-3249"],"issn-type":[{"value":"2643-3230","type":"print"},{"value":"2643-3249","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,16]]}}}